Liana Moussatos
Stock Analyst at Wedbush
(4.66)
# 203
Out of 4,415 analysts
45
Total ratings
57.81%
Success rate
35.84%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLSD Clearside Biomedical | Maintains: Outperform | $5 → $4 | $1.32 | +203.03% | 2 | Mar 13, 2024 | |
| VRNA Verona Pharma | Reiterates: Outperform | $33 | $15.75 | +109.52% | 6 | Mar 1, 2024 | |
| UTHR United Therapeutics | Reiterates: Outperform | $308 | $258.13 | +19.32% | 6 | Feb 22, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $75 | $107.00 | -29.91% | 4 | May 23, 2023 | |
| LQDA Liquidia | Downgrades: Underperform | $4 → $3 | $12.98 | -76.89% | 3 | Sep 1, 2022 | |
| ASND Ascendis Pharma | Maintains: Outperform | $128 → $117 | $141.10 | -17.08% | 3 | Mar 3, 2022 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $97 → $94 | $27.32 | +244.07% | 4 | Feb 28, 2022 | |
| XOMA XOMA Corporation | Downgrades: Neutral | n/a | $25.44 | - | 3 | Sep 7, 2021 | |
| AVTE Aerovate Therapeutics | Initiates: Outperform | n/a | $20.75 | - | 1 | Jul 26, 2021 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Neutral | n/a | $1.70 | - | 2 | Jan 29, 2021 | |
| IMUX Immunic | Initiates: Outperform | n/a | $1.33 | - | 1 | Jun 5, 2020 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | n/a | $83.80 | - | 4 | Mar 2, 2020 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | n/a | $3.28 | - | 3 | Feb 10, 2020 | |
| RGLS Regulus Therapeutics | Downgrades: Neutral | n/a | $2.69 | - | 3 | Jul 10, 2018 |
Clearside Biomedical
Mar 13, 2024
Maintains: Outperform
Price Target: $5 → $4
Current: $1.32
Upside: +203.03%
Verona Pharma
Mar 1, 2024
Reiterates: Outperform
Price Target: $33
Current: $15.75
Upside: +109.52%
United Therapeutics
Feb 22, 2024
Reiterates: Outperform
Price Target: $308
Current: $258.13
Upside: +19.32%
Blueprint Medicines
May 23, 2023
Reiterates: Outperform
Price Target: $75
Current: $107.00
Upside: -29.91%
Liquidia
Sep 1, 2022
Downgrades: Underperform
Price Target: $4 → $3
Current: $12.98
Upside: -76.89%
Ascendis Pharma
Mar 3, 2022
Maintains: Outperform
Price Target: $128 → $117
Current: $141.10
Upside: -17.08%
Pacira BioSciences
Feb 28, 2022
Maintains: Outperform
Price Target: $97 → $94
Current: $27.32
Upside: +244.07%
XOMA Corporation
Sep 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $25.44
Upside: -
Aerovate Therapeutics
Jul 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.75
Upside: -
Lexicon Pharmaceuticals
Jan 29, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.70
Upside: -
Immunic
Jun 5, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.33
Upside: -
BioMarin Pharmaceutical
Mar 2, 2020
Maintains: Outperform
Price Target: n/a
Current: $83.80
Upside: -
Aquestive Therapeutics
Feb 10, 2020
Maintains: Outperform
Price Target: n/a
Current: $3.28
Upside: -
Regulus Therapeutics
Jul 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $2.69
Upside: -